MagForce (MF6) - H117: EIB funding to accelerate rollout

13:30 EDT 8 Oct 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - MagForce: New financing from the European Investment Bank (EIB) of up to €35m will support NanoTherm’s European rollout for treatment of both brain and prostate cancer patients. In the US, a second clinical treatment site has been established in Texas and the IDE approval process with the FDA continues. In H117, the net loss for the period was €3.0m (H116: €3.2), while gross cash as of 30 June 2017 stood at €7.7m but does not include any drawdowns from the EIB loan, which was signed post period.

Original Article: MagForce (MF6) - H117: EIB funding to accelerate rollout


More From BioPortfolio on "MagForce (MF6) - H117: EIB funding to accelerate rollout"

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...